Rare Breed Triggers Patent

This docket consolidates a large, active patent-assertion campaign brought by a firearms-accessory manufacturer and its affiliated patent-holding entity against dozens of competing sellers of forced-reset trigger devices. Centralized in the Eastern District of Texas in 2026, the docket has grown quickly to 95 pending actions, reflecting an assertion strategy that has expanded to more than 130 total infringement suits, with the plaintiff group also seeking a consolidated preliminary injunction across the defendant population.

This is not a plaintiff-side funding opportunity in the conventional sense: the patent holder bringing these claims is well-resourced and litigating from a position of commercial and regulatory strength, including a federal settlement that resolved a separate regulatory dispute over its own products and support from a federal agency's filed statement of interest favoring injunctive relief against competitors. The more realistic capital conversation, where one exists at all, sits with individual defendant retailers or smaller manufacturers facing simultaneous infringement claims and potential injunctions, though litigation finance conventionally funds plaintiffs pursuing affirmative recovery rather than defendants resisting injunctive relief, which limits how directly Criterica Capital's products apply here.

Where this docket has real analytical value is as a live example of a single, well-capitalized patent holder using a large-scale, multi-defendant assertion campaign combined with regulatory alignment to reshape an entire competitive market through litigation rather than through product competition alone. A structure and litigation brief tracking the injunction posture across the defendant population is available for firms with a direct commercial stake in this specific market.

Pre-settlement funding is a non-recourse purchase of a portion of the proceeds of a pending legal claim — not a loan. If the case does not result in a recovery, nothing is owed. Rates, fees, and repayment terms are disclosed in full in the funding agreement, which the applicant’s attorney reviews before signing. Availability and terms vary by state.